DEDICATED SUPPORT FOR PATIENTS PRESCRIBED MAYZENT®
Alongside™ MAYZENT is committed to providing the right support, right when your patients need it. We’ll adapt to your process and your schedule—so you and your patients have clarity and know what to expect.
Alongside™ MAYZENT is committed to providing the right support, right when your patients need it. We’ll adapt to your process and your schedule—so you and your patients have clarity and know what to expect.
GET YOUR PATIENTS STARTED IN JUST 2 STEPS—ASSESSMENTS AND INITIATION
STEP 1: ASSESSMENTS
GET YOUR PATIENTS STARTED IN JUST 2 STEPS—ASSESSMENTS
AND INITIATION
STEP 1: ASSESSMENTS
Take care of all baseline assessments in just one or two visits*
-
Assessments may be available in your patient's home or at your office†
-
Using the Start Form, select exactly what assessments we can assist with




Take care of all baseline assessments in just one or two visits*
-
Assessments may be available in your patient's home or at your office†
-
Using the Start Form, select exactly what assessments we can assist with




For information on all supported tests, download the Alongside MAYZENT Onboarding Brochure
DOWNLOAD

STEP 2: TREATMENT INITIATION
STEP 2: TREATMENT INITIATION
Start and help patients stay on track with treatment§
Once genotype results are available, you will determine your patient’s maintenance dose. Then, treatment with MAYZENT can begin immediately for all commercially insured and approved government-insured patients. Alongside MAYZENT offers:
-
Several first-dose observation (FDO) support options are available for your patients (most patients may not require an FDO)
-
Ongoing one-on-one patient assistance from dedicated Coordinators
-
Technology to help patients stay on track during initiation and throughout treatment
-
The MAYZENT Welcome Kit, information patients may need to start and stay on treatment


FDO is required for select patients with preexisting cardiac conditions.2 You can coordinate the FDO directly, or you can refer patients to Alongside MAYZENT to sponsor the FDO conveniently at the patient’s home for eligible patients.¶
STEP 2: TREATMENT INITIATION
Start and help patients stay on track with treatment§
Once genotype results are available, you will determine your patient’s maintenance dose. Then, treatment with MAYZENT can begin immediately for all commercially insured and approved government-insured patients. Alongside MAYZENT offers:
-
Several first-dose observation (FDO) support options are available for your patients (most patients may not require an FDO)
-
Ongoing one-on-one patient assistance from dedicated Coordinators
-
Technology to help patients stay on track during initiation and throughout treatment
-
The MAYZENT Welcome Kit, information patients may need to start and stay on treatment


FDO is required for select patients with preexisting cardiac conditions.2 You can coordinate the FDO directly, or you can refer patients to Alongside MAYZENT to sponsor the FDO conveniently at the patient’s home for eligible patients.¶

BROAD COVERAGE WITH MAYZENT3
For all commercially insured and government-insured patients:
Approximately
87 % ofpatient reimbursement claims
are being approved3#
In case of approval challenges, Novartis is able to support commercially insured patients as they start on MAYZENT with a free bridge supply until commercial insurance coverage is approved. Alongside MAYZENT can also refer eligible patients to the Novartis Patient Assistance Foundation.

BROAD COVERAGE WITH MAYZENT3
BROAD COVERAGE WITH MAYZENT3
For all commercially insured and government-insured patients:
87 % of
patient reimbursement claims
are being approved3#
In case of approval challenges, Novartis is able to support commercially insured patients as they start on MAYZENT with a free bridge supply until commercial insurance coverage is approved. Alongside MAYZENT can also refer eligible patients to the Novartis Patient Assistance Foundation.
ADDITIONAL PATIENT SUPPORT WITH ALONGSIDE MAYZENT
Alongside MAYZENT provides patients with access & financial support options, as well as additional tools, resources, and services to help them stay on track.
Strong access for commercially insured patients
-
Dedicated reimbursement support
-
Financial support information
-
For commercially insured patients, the Bridge Program covers all drug costs while coverage is pursued for up to 1 year
-
Patient adherence support
-
$0 Rx co-pay and additional medical co-pay support for commercially insured patients**
-
Technology to help patients stay on track during initiation and throughout treatment
Strong access for commercially insured patients
-
Dedicated reimbursement support
-
Financial support information
-
For commercially insured patients, the Bridge Program covers all drug costs while coverage is pursued for up to 1 year
-
Patient adherence support
-
$0 Rx co-pay and additional medical co-pay support for commercially insured patients**
-
Technology to help patients stay on track during initiation and throughout treatment
GOING DIRECTLY THROUGH A SPECIALTY PHARMACY?
Your patients can enroll at start.mayzent.com for help with treatment initiation, ongoing one-on-one assistance from dedicated Coordinators, and access and reimbursement support
GOING DIRECTLY THROUGH A SPECIALTY PHARMACY?
Your patients can enroll at start.mayzent.com for help with treatment initiation, ongoing one-on-one assistance from dedicated Coordinators, and access and reimbursement support
RESOURCES AND TOOLS FOR YOUR ENROLLED PATIENTS
-
1-877-MAYZENT (1-877-629-9368) Helpline
available 8AM to 8PM Monday through Friday -
Dedicated one-on-one support for up to 2 years
-
Additional program-provided educational and adherence support content
-
Phone, text, and e-mail reminders
Novartis Field Reimbursement Managers (FRMs) and Case Managers are available to provide dedicated, in-office access and reimbursement support.
Novartis Alongside MAYZENT Coordinators help optimize your patient’s experience by delivering efficient patient initiation, including coordination and scheduling support.
GET PATIENTS STARTED ON MAYZENT®
ECG, electrocardiogram; MOA, mechanism of action; MOD, mechanism of disease; MS, multiple sclerosis; RMS, relapsing MS.
*For eligible and commercially insured patients.
†Free for commercially insured patients and those without insurance who are starting or restarting MAYZENT. Covered medical assessments include recommended blood tests, macular edema screening, electrocardiogram (ECG), and first-dose observation (FDO), as prescribed. Skin examinations are also recommended prior to or shortly after initiation but are not currently covered by the Alongside MAYZENT program. Macular edema screening is available in select areas only. Health care providers overseeing FDO will evaluate preexisting conditions or concomitant medications that may preclude the patients from completing their FDO. This offer is not valid for medical assessments (i) performed in RI, (ii) for which payment may be made in whole or in part under federal or state health care programs, including, but not limited to, Medicare or Medicaid, or (iii) where prohibited by law. There is a cash-pay option for residents of RI choosing to use a Program-sponsored medical facility. No purchase required. This Program is subject to termination or modification at any time.
‡A CYP2C9 genotype blood test is available at no cost to any patient who is being considered for treatment with MAYZENT. Limitations may apply. The cost of the test may not be billed to any third-party payer. Providers are responsible for obtaining patient consent for genetic testing in accordance with all applicable laws. This Program is not contingent on any orders or purchase of products or services from LabCorp or Novartis. This Program is subject to termination or modification at any time.
§Once appropriate maintenance dose has been determined based on genotype results.
||As of March 2022.
¶Listed services are for eligible commercial patients. For questions regarding services for your commercially and government-insured patients, see contact information above.
#As of August 2021.3
**Limitations apply. Up to an $18,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this Program without notice. See complete Terms & Conditions for details at www.mayzent.com.
References: 1. Data on file. Mayzent FDO Analysis. Novartis Pharmaceuticals Corp; March 2022. 2. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 3. Data on file. Mayzent Approval Rate Analysis. Novartis Pharmaceuticals Corp; August 2021.